Mitsubishi UFJ Trust & Banking
PTGX icon

Mitsubishi UFJ Trust & Banking’s Protagonist Therapeutics PTGX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Buy
+3,541
New +$370K ﹤0.01% 1104
2025
Q3 		– Sell
-5,975
Closed -$330K – 1136
2025
Q2 		$330K Buy
+5,975
New +$287K ﹤0.01% 944

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's PTGX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 3,541 shares worth $434K. The stake represents ﹤0.01% of the portfolio and ranks #1104 among its holdings. This is a return to the name: Mitsubishi UFJ Trust & Banking previously reported a position in PTGX as recently as Q2 2025.

Mitsubishi UFJ Trust & Banking first reported a position in PTGX in Q2 2025 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Mitsubishi UFJ Trust & Banking held 3,541 shares of Protagonist Therapeutics worth $434K as of Q2 2026.
  • Protagonist Therapeutics was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1104 holding.
  • Mitsubishi UFJ Trust & Banking first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.